GILEAD SCIENCES, INC.
GILD evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $180.82B
- Lead Asset:
- lenacapavir (Phase 2)
What it means
What to watch
Prepared research question
What matters most for GILD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GILD
Gilead Sciences is a biopharmaceutical company focused on HIV, oncology, and inflammation, with a pipeline entering an execution phase and a recent large net loss driven by acquisition costs.
Key risk: Large net loss from R&D spend
BioSniper Score
Based on 5 of 6 signals
Market Cap
$180.82B
Cash Runway
—
Lead Asset
lenacapavir (Phase 2)
Next Catalyst
Patent_Expiry · Oct 14, 2031Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 44 clinical trials · 8 catalysts · 1 FDA decision for GILEAD SCIENCES, INC..
Gilead Sciences is a biopharmaceutical company focused on HIV, oncology, and inflammation, with a pipeline entering an execution phase and a recent large net loss driven by acquisition costs.
- Total revenue of $7,803.0M and net income of -$10,496.0M as of 2026-06-30 [sec].
- Shareholders' equity of $11,829.0M as of 2026-06-30 [sec].
- Phase 3 IDEAL study for Livdelzi (seladelpar) in primary biliary cholangitis met its primary endpoint [news · published 2026-06-11].
- Acquired Tubulis GmbH in April 2026 to strengthen oncology pipeline with next-generation antibody-drug conjugates [news · published 2026-04-07].
- Expects to launch a weekly oral HIV prevention drug in Q1 2027 [news · published 2026-09-15].
What works
- HIV prevention and treatment franchises show double-digit commercial growth, with momentum in PrEP [news · published 2026-08-24] [news · published 2026-08-07].
- Oncology pipeline is advancing with over 25 abstracts presented at ASCO and EHA 2026, including solid tumors and hematologic malignancies [news · published 2026-05-21].
- Livdelzi (seladelpar) achieved statistically significant results in the Phase 3 IDEAL study for primary biliary cholangitis [news · published 2026-06-11].
- Acquisition of Tubulis adds potentially best-in-class ADC platform to the oncology pipeline [news · published 2026-04-07].
What to weigh
- Net loss of $10,496.0M as of 2026-06-30, largely driven by over $11 billion in acquired R&D expenses [sec] [news · published 2026-08-24].
- Significant patent expiries for key HIV drugs (e.g., emtricitabine/tenofovir alafenamide) begin in 2032, posing long-term revenue risk [catalyst].
- The company is at an 'inflection point' and must successfully execute on pipeline programs to justify large R&D investments [news · published 2026-09-15].
- Oncology and inflammation programs are still in development and have not yet contributed significant revenue [news · published 2026-09-10].
From the filings
Quoted directly from source documents.
Gilead posted a large net loss in Q2 2026 due to acquired R&D expenses.
“It was created by more than $11 billion in acquired research and development expenses”
News · August 24, 2026
Livdelzi (seladelpar) met its primary endpoint in the Phase 3 IDEAL study.
“Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving”
News · June 11, 2026
Gilead expects to launch a weekly oral HIV prevention drug in Q1 2027.
“Gilead expects weekly oral HIV prevention drug launch in Q1 2027”
News · September 15, 2026
Gilead acquired Tubulis to strengthen its oncology ADC pipeline.
“Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH”
News · April 7, 2026
Catalyst timeline
- 2031-10-14 · Patent_Expiry · AMBRISENTAN — Patent expiry for NDA022081; may open market to generic competition.
- 2032-08-15 · Patent_Expiry · EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE — Patent expiry for NDA208215; potential revenue impact from generics.
- 2032-08-15 · Patent_Expiry · EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE — Patent expiry for NDA208351; affects a key HIV combination product.
- 2032-08-15 · Patent_Expiry · TENOFOVIR ALAFENAMIDE FUMARATE — Patent expiry for NDA208464; may impact tenofovir alafenamide franchise.
- 2032-10-06 · Patent_Expiry · COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE — Patent expiry for NDA207561; another HIV combination at risk.
- 2036-11-08 · Patent_Expiry · BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE — Patent expiry for NDA210251 (Biktarvy); major HIV product.
- 2040-11-25 · Patent_Expiry · LENACAPAVIR SODIUM — Patent expiry for NDA220018; long-acting HIV drug.
- 2041-08-28 · Patent_Expiry · LENACAPAVIR SODIUM — Patent expiry for NDA215974; additional lenacapavir patent.
Risks & what to watch (3)›
Key risks
- Large net loss from R&D spend — Net loss of $10.5B as of 2026-06-30, driven by >$11B in acquired R&D expenses [sec] [news].
- Patent expiries on core HIV drugs — Key HIV patents expire starting 2032, threatening long-term revenue [catalyst].
- Pipeline execution risk — Company at 'inflection point' needing successful pipeline launches to justify investments [news].
What to watch
- Launch of weekly oral HIV prevention drug expected in Q1 2027 [news · published 2026-09-15].
- Progress of Livdelzi (seladelpar) in primary biliary cholangitis following Phase 3 IDEAL study results [news · published 2026-06-11].
- Integration and pipeline advancement from the Tubulis ADC acquisition [news · published 2026-04-07].
- Upcoming patent expiries on key HIV drugs starting in 2032 [catalyst].
Sources: Catalysts · News · Generated October 11, 2026 · How we verify sources →
Run GILEAD SCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GILEAD SCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.17 · 0% dilution
Lead: Approved
2 candidates
8 upcoming, next in ~1826d
0 buys · 29 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2,290
Total value held
$140.18B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 119,010,973 | $16.59B |
| vanguard capital management llc | 80,654,776 | $11.24B |
| fmr llc | 71,906,290 | $10.02B |
| state street corp | 59,858,585 | $8.34B |
| capital world investors | 41,283,933 | $5.75B |
| vanguard portfolio management llc | 35,129,465 | $4.90B |
| jpmorgan chase & co | 33,992,410 | $4.63B |
| geode capital management, llc | 29,726,052 | $4.14B |
| capital research global investors | 27,127,533 | $3.78B |
| dodge & cox | 24,250,826 | $3.38B |
Showing top 10 of 2,290 institutional holders of GILEAD SCIENCES, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 1.8%
- Days to cover
- 3.9
- Shares short
- 22,751,109
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GILD short interestGovernance
Frequently asked questions
What is the AI investment thesis for GILEAD SCIENCES, INC.?
Gilead Sciences is a biopharmaceutical company focused on HIV, oncology, and inflammation, with a pipeline entering an execution phase and a recent large net loss driven by acquisition costs.
What is GILEAD SCIENCES, INC.'s lead drug candidate?
GILEAD SCIENCES, INC.'s most advanced tracked candidate is lenacapavir (Phase 2) for HIV-1-infection; Pre-Exposure Prophylaxis of HIV Infection; HIV-1 Infection.
What is GILEAD SCIENCES, INC.'s next catalyst?
GILEAD SCIENCES, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA022081" — expected October 14, 2031.
Who is the CEO of GILEAD SCIENCES, INC.?
Mr. Daniel Patrick O'Day is the chief executive officer of GILEAD SCIENCES, INC. (GILD).
Where is GILEAD SCIENCES, INC. headquartered?
GILEAD SCIENCES, INC. (GILD) is headquartered in Foster City, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.